suspension buvable

DRUG3 trials

Sponsors

The University Of Birmingham, Centre Hospitalier Universitaire Vaudois, Assistance Publique Hopitaux De Paris

Conditions

Antifungal prophylaxis in patients with acute myeloid leukemiaHigh risk relapsed neuroblastoma (relapsed or progressed after being defined as High Risk at any time following diagnosis or progressed/relapsed as high-risk neuroblastoma)Major patients intoxicated by functional toxicant(s)hospitalized in intensive care and intubated.which is histologically proven as per International Neuroblastoma Staging System (INSS) definition.

Phase 1

BEACON 2: A Multi-Arm, Multi-Stage Platform Trial For Relapsed Neuroblastoma

Not yet recruitingCTIS2024-516115-24-00

The University Of BirminghamHigh risk relapsed neuroblastoma (relapsed or progressed after being defined as High Risk at any time following diagnosis or progressed/relapsed as high-risk neuroblastoma), which is histologically proven as per International Neuroblastoma Staging System (INSS) definition.

Target: 102Updated: 2025-12-15

Phase 2

DIMREATOX study - Reduction in digestive absorption of toxic substances by combined digestive decontamination in intensive care - randomized single-center study

Not yet recruitingCTIS2024-518739-12-00

Assistance Publique Hopitaux De Parishospitalized in intensive care and intubated., Major patients intoxicated by functional toxicant(s)

Target: 200Updated: 2025-12-19

Phase 4

PTX3 genetically stratified randomized double-blinded allocation event-driven clinical trial for antifungal prophylaxis in patients with acute myeloid leukemia

Not yet recruitingCTIS2024-517211-79-00

Centre Hospitalier Universitaire VaudoisAntifungal prophylaxis in patients with acute myeloid leukemia

Target: 153Updated: 2024-10-17